CorMedix Inc Total Liabilities
CorMedix Inc total liabilities. Based on the latest financial reports, CorMedix Inc (CRMD) has total liabilities worth $420.83 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check CorMedix Inc (CRMD) asset resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of CorMedix Inc (2008–2025)
Total liabilities of CorMedix Inc from 2008 to 2025. This chart illustrates how CorMedix Inc's total liabilities have evolved over time, based on quarterly financial data. Explore CorMedix Inc long-term investment allocation to see how much of total assets are deployed in long-term investments.
CorMedix Inc Competitors by Total Liabilities
The table below lists competitors of CorMedix Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
PureTech Health PLC
NASDAQ:PRTC
|
USA | $229.03 Million |
|
Lifecome Biochemistry Co Ltd
SHE:002868
|
China | CN¥656.81 Million |
|
L&C Bio Co. Ltd
KQ:290650
|
Korea | ₩231.24 Billion |
|
Objective Corporation Ltd
AU:OCL
|
Australia | AU$86.59 Million |
|
Phat Dat Real Estate Development Corp
VN:PDR
|
Vietnam | ₫14.04 Trillion |
|
Star Gas Partners LP
NYSE:SGU
|
USA | $621.24 Million |
|
Norma Group AG NA O.N.
XETRA:NOEJ
|
Germany | €713.83 Million |
|
Bank Artos Indonesia Tbk PT
JK:ARTO
|
Indonesia | Rp30.62 Trillion |
Liability Composition Analysis (2008–2025)
This chart breaks down CorMedix Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is CorMedix Inc's balance sheet.
Liquidity & Leverage Metrics
CorMedix Inc Total Liabilities Ratios Explained
CorMedix Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.01 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.04 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.51 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CorMedix Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CorMedix Inc (2008–2025)
The table below shows the annual total liabilities of CorMedix Inc from 2008 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $420.83 Million | +1130.92% |
| 2024-12-31 | $34.19 Million | +186.88% |
| 2023-12-31 | $11.92 Million | +70.77% |
| 2022-12-31 | $6.98 Million | +13.52% |
| 2021-12-31 | $6.15 Million | +20.89% |
| 2020-12-31 | $5.09 Million | -12.77% |
| 2019-12-31 | $5.83 Million | -58.03% |
| 2018-12-31 | $13.89 Million | +121.89% |
| 2017-12-31 | $6.26 Million | +53.00% |
| 2016-12-31 | $4.09 Million | +32.41% |
| 2015-12-31 | $3.09 Million | +111.18% |
| 2014-12-31 | $1.46 Million | -79.07% |
| 2013-12-31 | $6.99 Million | +329.20% |
| 2012-12-31 | $1.63 Million | +23.43% |
| 2011-12-31 | $1.32 Million | -17.14% |
| 2010-12-31 | $1.59 Million | -90.60% |
| 2009-12-31 | $16.93 Million | +24.09% |
| 2008-12-31 | $13.65 Million | -- |
About CorMedix Inc
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Pi… Read more